PAVmed Inc. Series Z Warrant - PAVMZ STOCK NEWS

Lucid Diagnostics Inc. (Nasdaq: LUCD) has announced the publication of three clinical utility studies demonstrating the real-world clinical utility of Lucid's EsoGuard Esophageal DNA test to detect esophageal precancer. The studies document near-perfect concordance between EsoGuard results and the prescribing physician's decision whether to refer patients for upper endoscopy, with 100 percent of EsoGuard-positive patients being referred for confirmatory upper endoscopy. These results eliminate the need for hundreds of costly, invasive, and inconvenient endoscopies, demonstrating that EsoGuard allows physicians to appropriately triage at-risk patients, consistent with established professional society guidelines, and ensure cost-effective utilization of endoscopy in esophageal precancer detection.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announces the distribution of approximately 3.3 million shares of Lucid common stock to its shareholders as of January 15, 2024. Each PAVmed shareholder will receive a stock dividend of approximately 41 shares of Lucid common stock for every 100 shares of PAVmed common stock they own as of the record date.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announces a dividend of approximately 3.3 million shares of Lucid Diagnostics Inc. (Nasdaq: LUCD) common stock and a 1-for-15 reverse stock split to be effective as of market open on December 7, 2023.

Lucid Diagnostics Inc. (Nasdaq: LUCD) strengthens its executive team with two industry veterans, Natalie S. Carfora and James M. Fricchione, joining as Vice President, Market Access, and Vice President, Employer Markets, respectively. Shaun M. O'Neil is promoted to President and COO. These appointments aim to drive EsoGuard® payor coverage and secure direct contracts with employers and self-insured entities, crucial for translating test volume growth into revenue. Natalie Carfora brings over a decade of experience in market access and sales, while Jim Fricchione has over two decades of national health benefits experience. Shaun O'Neil, an industry veteran, has been instrumental in designing and building Lucid's commercial infrastructure and overseeing its commercial strategy.

PAVmed Inc. (NASDAQ: PAVM, PAVMZ) reported a 392% sequential increase in Lucid's quarterly revenue, with Veris Health's expansion efforts underway. The quarterly financial results were presented, and a webcast is scheduled for tomorrow at 8:30 AM EST.

Lucid Diagnostics Inc. (Nasdaq: LUCD) reports a 17% increase in Quarterly EsoGuard® test volume and a 392% increase in revenue sequentially. The company's CLIA-certified clinical laboratory performed 2,575 commercial EsoGuard® Esophageal DNA Tests in Q3 2023. Lucid's Q3 revenue was $783K, with operating expenses of $11.9 million. Lucid had cash and cash equivalents of $24.1 million as of September 30, 2023.

LUCD - Lucid Diagnostics Inc. (Nasdaq: LUCD) announced the launch of EsoGuard 2.0, an enhanced esophageal DNA test with improved performance and lower costs. The company will also host an Investor Day event in New York City on December 13, 2023, to discuss commercial progress and the recent expansion of clinical utility and validity data.

Lucid Diagnostics Inc., a cancer prevention medical diagnostics company, announced that its Chairman and CEO, Dr. Lishan Aklog, will present at the Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum on November 16, 2023, in New York City. The presentation will take place at 10:00am EST, and management will be available for one-on-one meetings with investors at the conference.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) will host a business update conference call and webcast on November 15, 2023, at 8:30 AM EST. The call will provide a business update and overview of operations and growth strategy by Lishan Aklog, M.D., Chairman and CEO. Dennis McGrath, President and CFO, will discuss the third-quarter 2023 financial results. The webcast will be available on the company's website. Replay will be available for 30 days.